Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide dose-ranging trial in non-alcoholic steatohepatitis
NL-OMON47918Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Novo Nordisk. Primary endpoint: NASH resolution without worsening of fibrosis. Started Feb 2017; status: active, not recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON47918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47918.